Cue Biopharma, Inc.
CUEHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCue Biopharma, Inc., a clinical-stage therapeutics company, focuses on developing various therapies for immunological disorders. The company carries a $140.5M market cap, placing it firmly in the micro-cap category. The company's lead asset is CUE-221, an anti-IgE antibody with a dual-mechanism of action currently in Phase 2 development for allergic diseases.
Market Cap
$140.5M
Beta
2.46
P/E (TTM)
—
P/E (Fwd)
-69.71
EPS (TTM)
$-4.91
EPS (Fwd)
$-0.48
ROE
-138.5%
ROA
-46.1%
Cash
$17.4M
Total Debt
$3.4M
Free CF
-$14.9M
52W Change
24.1%
Annual Financials
Cash vs Debt
Where CUE stands vs its 150-day and 200-day moving averages
As of the July 6, 2026 close, CUE finished 79.77% above its 150-day moving average ($15.72) and 64.40% above its 200-day moving average ($17.19). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CUE overbought or oversold?
At the July 6, 2026 close, CUE's RSI(14) was 52.1, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $17.4M in cash comfortably exceeding the $3.4M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$14.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -138.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $1.2M (2022) to $27.5M (2025), reflecting a 2106% increase over the period.
A beta of 2.46 means CUE is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, CUE has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Cue Biopharma, Inc. and its sector.